Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319009 | 0.92 | KCNH2 (0.56) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6320235 | 0.89 | KCNH2 (0.66) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6318402 | 0.88 | KCNH2 (0.56) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6319483 | 0.86 | KCNH2 (0.53) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6320576 | 0.85 | KCNH2 (0.55) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6319481 | 0.83 | KCNH2 (0.65) | KCNH2 | |
| SCHEMBL6325235 | 0.83 | KCNH2 (0.65) | KCNH2 | |
| SCHEMBL6319279 | 0.83 | KCNH2 (0.54) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6317438 | 0.83 | KCNH2 (0.52) | KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6318317 | 0.81 | KCNH2 (0.52) | KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | KCNH2 491/4885CHRM1 4046/4885HTR2A 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.